Federated Computing for Clinical Research

Collaborate across institutions without surrendering control of your data

Clinical research depends on multi-site collaboration — yet the obligations protecting patient data make centralizing records legally, ethically, and scientifically untenable. Federated computing resolves this tension. Institutions share knowledge, not records.

Patient records never leave the institution
Full IRB and consent alignment preserved
GDPR & HIPAA compliant by architecture
Cryptographically secured aggregation
0
Patient records transferred to any central repository
100%
Investigator custody retained at each participating site
Multi-site
Statistical power — without pooling a single data file
Principle 01
Data stays local
Patient records never leave the institutional boundary. Governance, custody, and consent alignment remain with the originating site throughout every analysis.
Principle 02
Quality before federation
Data quality is validated within each site before participation. Harmonization to CDISC, OMOP, SNOMED, and LOINC standards is a prerequisite — not an afterthought.
Principle 03
Shared learning, not shared files
Collaboration happens through encrypted statistical contributions. No site ever observes another site's individual patient data — only the aggregated learning benefits are shared.
The problem with centralization

Why pooling patient data is not the answer

Multi-site research has long assumed that meaningful collaboration requires data aggregation. In practice, centralized repositories create obligations that most institutions cannot honor — and risks that patients did not consent to bear.

"Every time we ask a site to transfer patient data to a central repository, we are asking them to go back to their IRB, reinterpret their consent forms, and accept liability they were never designed to carry."

Centralized data pooling

  • Data transferred to a third-party repository
  • Custody and governance shared or unclear
  • Consent scope may not cover secondary transfer
  • Cross-jurisdictional data movement exposure
  • IRB re-review typically required
  • Audit trail fragmented across systems
  • Re-identification risk scales with pool size
VS

Federated computing

  • Data remains within the institutional boundary
  • Investigator retains full custody throughout
  • Consistent with original consent terms
  • No cross-border patient data movement
  • Existing IRB approval preserved
  • Complete local audit trail maintained
  • Re-identification risk contained at source
Data quality

Quality must be established before collaboration begins

Federated analyses derive their validity from the quality of data at each participating site. Poor source data does not produce uncertain results — it produces confidently wrong ones. Data quality standards are a prerequisite for federation, not a downstream concern.

Completeness & missingness analysis

Systematic missingness — when data is absent not at random — introduces bias that scales across a federated network. Each site must characterize its missingness patterns and document imputation strategies before contributing to any federated analysis.

Relevant standard: ICH E9(R1) — estimands and sensitivity analysis in clinical trials

Harmonization to controlled vocabularies

Multi-site data routinely uses inconsistent variable coding, unit conventions, and clinical terminology. Harmonization to SNOMED CT, LOINC, MedDRA, and alignment to CDISC SDTM or OMOP CDM is required before data can be meaningfully federated.

Standards: CDISC CDASH / SDTM / ADaM; OMOP CDM for real-world data

Temporal integrity

Clinical data is inherently time-ordered. Timestamp errors, visit-date ambiguities, and event sequencing issues create serious confounding in longitudinal federated analyses. Temporal validation is a site-level requirement prior to federation.

Critical for: time-to-event analyses, survival modeling, longitudinal RWE studies

Source data verifiability

Federated study results submitted to regulators must be traceable to auditable source data at each contributing site. Local data management practices must meet the same evidentiary standards expected of centralized trial databases.

Regulatory relevance: 21 CFR Part 11; EU Annex 11; ICH E6(R3) GCP
Architecture

How federated computing works

Rather than moving data to a central analytical environment, the analysis protocol is distributed to each participating institution. Each site executes the protocol locally and returns only encrypted statistical contributions — never patient records.

Federated architecture — multi-site clinical research network

Site A
Academic medical center — local EHR, trial database, registry data
Data stays local
Site B
Community hospital — local EHR, trial database, registry data
Data stays local
Site C
Regional network — local EHR, trial database, registry data
Data stays local
Each site executes the analysis protocol locally — only encrypted aggregate statistics are transmitted outbound
Secure aggregation layer
Statistical contributions combined using cryptographic protocols — differential privacy applied to prevent inference of individual site contributions
Aggregate statistics only — no patient records
Consolidated research findings returned to all participating investigators with full provenance documentation
Research-grade evidence
Multi-site findings with full statistical power — reproducible, auditable, and regulatorily defensible

Differential privacy

Mathematically calibrated noise is added to aggregate statistics before transmission, ensuring it is computationally infeasible to reconstruct individual patient records — or even individual site contributions — from the combined output, even under adversarial conditions.

Secure multi-party computation

Cryptographic protocols allow participating sites to jointly compute aggregate results without any party — including the coordinating institution — observing another site's individual statistical contributions. Particularly relevant for commercially sensitive or competitive research contexts.

Complete audit trails at every site

Every federated analysis round is logged locally with cryptographic signatures. Each site retains a complete record of what analysis protocol was executed, what data elements were accessed, and what statistical outputs were transmitted — satisfying both regulatory and IRB audit requirements independently of the coordinating institution.

Site-level consent scope enforcement

Participation in any federated study is opt-in at the site and protocol level. Data elements included in any analysis are automatically constrained to those covered by the relevant consent framework at each site. Sites may withdraw from any analysis round without affecting their participation in others.

Research applications

What federated computing enables

By preserving institutional data governance while enabling multi-site statistical collaboration, federated computing opens research questions that centralized approaches cannot safely address.

01
Protocol Design

Feasibility assessment across a federated network

Before a trial is initiated, federated queries across participating registries and EHR networks characterize the eligible patient population at each site — informing sample size estimates, site selection, and protocol parameters without any patient-level data transfer.

02
Trial Conduct

Distributed safety surveillance across sites

Federated safety monitoring aggregates adverse event signals across all participating sites in real time, producing network-level safety intelligence that no single site could observe alone — while each site's patient records remain entirely local and under local governance.

03
Analysis

Federated synthetic control arms from real-world data

Where randomized placebo controls are infeasible, federated analyses of real-world EHR data construct synthetic comparator populations from multiple institutions — substantially increasing statistical validity compared to single-site historical controls, without pooling records.

04
Analysis

Heterogeneity of treatment effect across populations

Federated subgroup analyses identify differential response patterns across institutions, geographic regions, and patient populations — producing reproducible HTE findings with the statistical power that only network-scale data provides.

05
Post-Approval Evidence

Real-world effectiveness across routine clinical practice

Federated analyses of post-approval EHR and registry data characterize how interventions perform across the full diversity of clinical practice — comorbidity profiles, prescribing patterns, and patient populations not represented in the original trial — without requiring any patient data to leave its source institution.

Regulatory alignment

Governance posture for an evolving regulatory landscape

Regulatory frameworks for research data governance are tightening across all major jurisdictions. Federated computing is structurally aligned with the direction of travel — satisfying data minimization, provenance, and audit-readiness requirements without special accommodation.

FDA (United States)
FDA guidance on real-world evidence emphasizes data provenance, fitness for purpose, and audit-readiness. Federated studies produce locally maintained audit trails and analysis logs that satisfy these requirements without centralized data custody.
EMA / GDPR (European Union)
GDPR's data minimization and purpose limitation principles are structurally satisfied by federated architectures. The EMA's increasing emphasis on data quality for regulatory submissions is addressed through site-level standards conformance prior to federation.
ICH Guidelines
ICH E8(R1) and E9(R1) principles on data quality, estimands, and sensitivity analysis apply directly to federated studies. ICH E6(R3) GCP requirements for source data verifiability are preserved through local audit trails at each participating site.

Discuss your research network's requirements

Our team includes clinical data scientists and regulatory specialists who can evaluate federated computing for your specific protocol and institutional context.